Immuno-Oncology | Specialty

Bristol Myers Squibb Withdraws Nivolumab SCLC Indication From US Market

December 30th 2020

December 30, 2020 - Bristol Myers Squibb has withdrawn nivolumab from the US market for the treatment of patients with small cell lung cancer who have experienced disease progression after a platinum-based chemotherapy and at least 1 other line of therapy.

Immunotherapy Combos Crowd Frontline NSCLC Landscape

December 30th 2020

Alex A. Adjei, MD, PhD, discusses frontline treatment options for patients with advanced non–small cell lung cancer, as well as some of the nuances of selecting the optimal therapy.

Immunotherapy Combos Take Next Step in Gynecologic Cancers

December 29th 2020

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.

Rohs Reflects on Therapeutic Approaches in Early- Vs Late-Stage Lung Cancer

December 28th 2020

Nicholas C. Rohs, MD, highlights the influx of clinical trials and the addition of immunotherapy in the adjuvant setting of lung cancer.

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies

December 28th 2020

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Nivolumab Plus Temozolomide/Radiotherapy Misses OS End Point in Glioblastoma Multiforme 

December 23rd 2020

December 23, 2020 — Nivolumab in combination with temozolomide and radiation treatment failed to result in a statistically significant improvement in overall survival in patients with newly diagnosed glioblastoma multiforme with MGMT promoter methylation following surgical resection of the tumor.

Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

December 21st 2020

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

FDA Grants Priority Review to Frontline Pembrolizumab/Chemo for Locally Advanced Unresectable or Metastatic Esophageal/GEJ Cancer

December 17th 2020

December 17, 2020 - The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment in patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Second-Line Motixafortide Plus Pembrolizumab/Chemo Substantially Improves Survival in Stage IV PDAC

December 16th 2020

December 16, 2020 - The combination of motixafortide plus pembrolizumab and chemotherapy was found to result in a substantial improvement in overall survival, progression-free survival, and overall response rate when used as a second-line treatment in patients with stage IV pancreatic ductal adenocarcinoma.

Nivolumab/Ipilimumab Combo Shows Antitumor Activity in Metastatic Uveal Melanoma

December 16th 2020

December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.

Immunotherapy Agents Drive Frontline Treatment Strategies in Advanced NSCLC

December 16th 2020

Several immunotherapeutic options are available for non–small cell lung cancer (NSCLC), allowing decisions to be made based on histology, PD-L1 expression, and patient preference in regard to their treatment goals. Looking ahead, there may also be efficacy in moving immunotherapy drugs up into the resectable, early-stage setting

Pembrolizumab/Lenvatinib Combo Improves Survival, Responses Over Chemo in Advanced Endometrial Cancer

December 16th 2020

December 16, 2020 - Pembrolizumab/lenvatinib has significantly improved survival and responses compared with chemotherapy in patients with advanced endometrial cancer who have received previous systemic treatment.

Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLC

December 16th 2020

Roy S. Herbst, MD, PhD, discusses biomarkers for immunotherapy response that are currently under investigation in non–small cell lung cancer (NSCLC).

Dr. Goldberg on the Evolving Role of Immunotherapy in NSCLC

December 16th 2020

Sarah B. Goldberg, MD, MPH, discusses the evolving role of immunotherapy in non–small cell lung cancer.

Immunotherapy Finds a Foothold in Metastatic Bladder Cancer, But Frontline Challenges Remain

December 14th 2020

The emergence of checkpoint inhibitors has transformed the second-line treatment of patients with metastatic bladder cancer. However, questions regarding the utility of immunotherapy in the frontline setting remain unanswered, leaving chemotherapy as the standard-of-care option.

Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma

December 14th 2020

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma

December 14th 2020

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

Sznol Advocates for More Awareness of Immune-Related Toxicities

December 14th 2020

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

Frontline Pembrolizumab Granted Positive EU Opinion in Metastatic MSI-H, dMMR CRC

December 11th 2020

December 11, 2020 - The European Medicine Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for pembrolizumab monotherapy for the frontline treatment of adult patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.